Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.02M | -4.16M | 7.23M | 8.86M | 6.37M |
| Total Depreciation and Amortization | 3.50M | 3.03M | 2.89M | 2.69M | 2.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -676.00K | 7.36M | 7.85M | 3.38M | 2.39M |
| Change in Net Operating Assets | 1.70M | -11.48M | -26.53M | -20.61M | -19.88M |
| Cash from Operations | -14.50M | -5.24M | -8.55M | -5.69M | -8.64M |
| Capital Expenditure | -1.25M | -1.33M | -1.27M | -1.06M | -1.09M |
| Sale of Property, Plant, and Equipment | 24.00K | 35.00K | 30.00K | 157.00K | 152.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.53M | 190.00K | 5.16M | 973.00K | -137.00K |
| Cash from Investing | 7.30M | -1.10M | 3.92M | 70.00K | -1.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 589.00K | 24.42M | 25.87M | 26.88M | 27.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 107.00K | -3.47M | -3.59M | -3.96M | -4.33M |
| Cash from Financing | 696.00K | 20.95M | 22.27M | 22.92M | 22.88M |
| Foreign Exchange rate Adjustments | 1.17M | 489.00K | 254.00K | -128.00K | -139.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.33M | 15.10M | 17.90M | 17.18M | 13.03M |